AZ rejigs endpoints in key trial of durvalumab
Health systems should fund more treatments for chronic diseases, says EFPIA
2017 could be a bumper year for M&A – but Trump’s price control threats dominate
This week’s news
Application includes figures of heart rate monitoring armband and wristband.
Patients could be denied treatments, says BIA
Samsung to take on patent thicket surrounding Humira.
Industry giants such as AstraZeneca and Novartis are on board.
Multi-centre trial of Ortho-ATI technology planned for early 2017.
Afinitor finally recommended after rejection in 2011.
Settlement relates to investigation into Dermagraft sales.
Approval by May could put Keytruda in pole position
Project aims to improve population health management.
Sales of Humira could peak above $18 billion – CEO
Allergan to co-develop Parkinson’s drug with Lysosomal Therapeutics
PM under fire over A&E waiting times.